doi:10.1159/000521625

[1]

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

doi: 10.3322/caac.21492

[2]

Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–91.e1.

doi: 10.1053/j.gastro.2018.08.065

[3]

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.

doi: 10.1056/NEJMoa0708857

[4]

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.

doi: 10.1016/S1470-2045(08)70285-7

[5]

Keating GM. Sorafenib: a review in hepatocellular carcinoma. Target Oncol. 2017;12(2):243–53.

doi: 10.1007/s11523-017-0484-7

[6]

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73.

doi: 10.1016/S0140-6736(18)30207-1

[7]

Bruix J, da Fonseca LG, Reig M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2019;16(10):617–30.

doi: 10.1038/s41575-019-0179-x

[8]

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905.

doi: 10.1056/NEJMoa1915745

[9]

Chang TA, Sawhney R, Monto A, Ben Davoren J, Kirkland JA, Stewart L, et al. Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. HPB. 2008;10(6):405–11.

doi: 10.1080/13651820802356572

[10]

Yopp AC, Mansour JC, Beg MS, Arenas J, Trimmer C, Reddick M, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol. 2014;21(4):1287–95.

doi: 10.1245/s10434-013-3413-8

[11]

Cabibbo G, Celsa C, Calvaruso V, Petta S, Cacciola I, Cannavò MR, et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol. 2019;71(2):265–73.

doi: 10.1016/j.jhep.2019.03.027

[12]

Rich NE, Yopp AC, Singal AG. Medical management of hepatocellular carcinoma. J Oncol Pract. 2017;13(6):356–64.

doi: 10.1200/JOP.2017.022996

[13]

Mudumbi SK, Bourgeois CE, Hoppman NA, Smith CH, Verma M, Bakitas MA, et al. Palliative care and hospice interventions in decompensated cirrhosis and hepatocellular carcinoma: a rapid review of literature. J Palliat Med. 2018;21(8):1177–84.

doi: 10.1089/jpm.2017.0656

[14]

Johnson PJ, Qin S, Park JW, Poon RTP, Raoul JL, Philip PA, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase Ⅲ BRISKFL study. J Clin Oncol. 2013;31(28):3517–24.

doi: 10.1200/JCO.2012.48.4410

[15]

Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase Ⅲ trial. J Clin Oncol. 2015;33(2):172–9.

doi: 10.1200/JCO.2013.54.3298

[16]

Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase Ⅲ trial. J Clin Oncol. 2013;31(32):4067–75.

doi: 10.1200/JCO.2012.45.8372

[17]

Thomas MB, Garrett-Mayer E, Anis M, Anderton K, Bentz T, Edwards A, et al. A randomized phase Ⅱ open-label multi-institution study of the combination of bevacizumab and erlotinib compared to sorafenib in the first-line treatment of patients with advanced hepatocellular carcinoma. Oncology. 2018;94(6):329–39.

doi: 10.1159/000485384

[18]

Assenat E, Pageaux GP, Thézenas S, Peron JM, Bécouarn Y, Seitz JF, et al. Sorafenib alone vs. sorafenib plus GEMOX as 1 st -line treatment for advanced HCC: the phase Ⅱ randomised PRODIGE 10 trial. Br J Cancer. 2019;120(9):896–902.

doi: 10.1038/s41416-019-0443-4

[19]

Ciuleanu T, Bazin I, Lungulescu D, Miron L, Bondarenko I, Deptala A, et al. A randomized, double-blind, placebo-controlled phase Ⅱ study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma. Ann Oncol. 2016;27(4):680–7.

doi: 10.1093/annonc/mdw004

[20]

Abdel-Rahman O, Abdel-Wahab M, Shaker M, Abdel-Wahab S, Elbassiony M, Ellithy M. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol. 2013;30(3):655.

doi: 10.1007/s12032-013-0655-z

[21]

Koeberle D, Dufour J-F, Demeter G, Li Q, Ribi K, Samaras P, et al. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase Ⅱ trial (SAKK 77/08 and SASL 29). Ann Oncol. 2016 May;27(5):856–61.

doi: 10.1093/annonc/mdw054

[22]

Zhu AX, Rosmorduc O, Evans TRJ, Ross PJ, Santoro A, Carrilho FJ, et al. Search: a phase Ⅲ, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33(6):559–66.

doi: 10.1200/JCO.2013.53.7746

[23]

Yau T, Park JW, Finn RS, Cheng A-L, Mathurin P, Edeline J, et al. CheckMate 459: a randomized, multi-center phase Ⅲ study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30(Suppl 5):v851–934.

[24]

Cheng AL, Thongprasert S, Lim HY, Sukeepaisarnjaroen W, Yang TS, Wu CC, et al. Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. Hepatology. 2016;64(3):774–84.

doi: 10.1002/hep.28600

[25]

Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase Ⅱ–Ⅲ trial. J Clin Oncol. 2021;39(27):3002–11.

doi: 10.1200/JCO.21.00163

[26]

Exelixis and Ipsen announce cabozantinib in combination with an immune checkpoint inhibitor significantly improved progressionfree survival in phase 3 COSMIC-312 pivotal trial in patients with previously untreated advanced liver cancer [Internet]. 2021 [cited 2021 Aug 19]. Available from: https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/2021/06/09120111/Ipsen-Exelixis-COSMIC-312-28-June-2021.pdf.

[27]

Yeh ML, Kuo HT, Huang CI, Huang CF, Hsieh MY, Liang PC, et al. Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy. Kaohsiung J Med Sci. 2021;37(2):145–53.

doi: 10.1002/kjm2.12303

[28]

Sanoff HK, Chang Y, Lund JL, O’Neil BH, Dusetzina SB. Sorafenib effectiveness in advanced hepatocellular carcinoma. Oncologist. 2016;21(9):1113–20.

doi: 10.1634/theoncologist.2015-0478

[29]

Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence: what is it and what can it tell us? N Engl J Med. 2016;375(23):2293–7.

doi: 10.1056/NEJMsb1609216